Reproxalap ophthalmic solution (0.25%)
DrugReproxalap Ophthalmic Solution (0.25%) administered once.
NCT Number: NCT03494504
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Cornea Consultants of Arizon, Phoenix, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Reproxalap Ophthalmic Solution (0.25%) administered once.
Reproxalap Ophthalmic Solution (0.5%) administered once.
Vehicle Ophthalmic Solution administered once.
Time frame: Efficacy was assessed after a single dose; baseline was assessed approximately two weeks before dosing.
Subject-reported ocular itching score area under the curve from 10 to 60 minutes post allergen challenge using a 0 to 4 scale (0 = none, 4 = severe) was assessed. The least squares mean was derived from analysis of covariance of area under the curve with baseline as a covariate and treatment as a fixed effect The possible range for area under the curve least squares mean is 0 to 100, where a lower score is better.
Time frame: Efficacy was assessed after a single dose; baseline was assessed approximately two weeks before dosing.
The number of within subject 2-point responders (2-point reduction in itch score from 20-60 minutes post-challenge) using a 0 to 4 scale (0 = least, 4 = most) from the 5-minute post-challenge itch score at baseline was assessed.
Aldeyra Therapeutics, Inc.
Industry
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05234554
Allergic Conjunctivitis, Conjunctival Diseases
Mississauga, Ontario, Canada
View Trial DetailsNCT06602726
Allergic Conjunctivitis, Conjunctival Diseases
Andover, Massachusetts, United States
View Trial DetailsNCT06602739
Allergic Conjunctivitis, Conjunctival Diseases
Andover, Massachusetts, United States
View Trial DetailsNCT01471184
Allergic Conjunctivitis, Allergic Rhinitis
Mississauga, Ontario, Canada
View Trial Details